- Home
- GPRO vs CHRS Comparison
GPRO vs CHRS Comparison
Compare GPRO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRO
- CHRS
- Stock Information
- Founded
- GPRO 2004
- CHRS 2010
- Country
- GPRO United States
- CHRS United States
- Employees
- GPRO N/A
- CHRS N/A
- Industry
- GPRO Industrial Machinery/Components
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GPRO Consumer Discretionary
- CHRS Health Care
- Exchange
- GPRO Nasdaq
- CHRS Nasdaq
- Market Cap
- GPRO 193.5M
- CHRS 185.5M
- IPO Year
- GPRO 2014
- CHRS 2014
- Fundamental
- Price
- GPRO $1.10
- CHRS $1.57
- Analyst Decision
- GPRO Hold
- CHRS Strong Buy
- Analyst Count
- GPRO 1
- CHRS 4
- Target Price
- GPRO $1.50
- CHRS $5.38
- AVG Volume (30 Days)
- GPRO 1.7M
- CHRS 10.4M
- Earning Date
- GPRO 02-05-2025
- CHRS 11-06-2024
- Dividend Yield
- GPRO N/A
- CHRS N/A
- EPS Growth
- GPRO N/A
- CHRS N/A
- EPS
- GPRO N/A
- CHRS N/A
- Revenue
- GPRO $896,011,000.00
- CHRS $304,340,000.00
- Revenue This Year
- GPRO N/A
- CHRS $1.64
- Revenue Next Year
- GPRO N/A
- CHRS $16.98
- P/E Ratio
- GPRO N/A
- CHRS N/A
- Revenue Growth
- GPRO N/A
- CHRS 44.19
- 52 Week Low
- GPRO $1.09
- CHRS $0.66
- 52 Week High
- GPRO $3.60
- CHRS $3.70
- Technical
- Relative Strength Index (RSI)
- GPRO 36.52
- CHRS 67.08
- Support Level
- GPRO $1.21
- CHRS $1.45
- Resistance Level
- GPRO $1.36
- CHRS $1.85
- Average True Range (ATR)
- GPRO 0.06
- CHRS 0.22
- MACD
- GPRO -0.01
- CHRS 0.01
- Stochastic Oscillator
- GPRO 3.70
- CHRS 42.21
About GPRO GoPro Inc.
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.